Surgical Oncology Insight最新文献

{"title":"Contemporary survivorship care patterns for melanoma patients in Ontario, Canada: variability and opportunity","authors":"Valerie A. Francescutti ,&nbsp;Anastasia Gayowsky ,&nbsp;Gregory R. Pond ,&nbsp;Hsien Seow ,&nbsp;Elaine McWhirter ,&nbsp;Linda Lee ,&nbsp;Elie Isenberg-Grzeda ,&nbsp;Frances C. Wright ,&nbsp;Nicole J. Look Hong","doi":"10.1016/j.soi.2026.100234","DOIUrl":"10.1016/j.soi.2026.100234","url":null,"abstract":"<div><h3>Purpose</h3><div>Survivorship includes surveillance for detection of cancer recurrence and addressing treatment-related side effects that may impact quality of life. Currently, melanoma survivorship is provider-driven, and little is known about survivorship care provision. We evaluated contemporary patterns of melanoma survivorship care based on physician visits and imaging study completion using population-level data from Ontario, Canada.</div></div><div><h3>Methods</h3><div>Patients with stage I-III invasive cutaneous melanoma diagnosed from 2007 to 2019 were retrospectively identified from the Ontario Cancer Registry. Linked administrative databases were used to identify patient and disease characteristics, treatments received, and implemented survivorship care. Descriptive data was analyzed based on the receipt of surgery-only or surgery + adjuvant therapy.</div></div><div><h3>Results</h3><div>From 2007–2019, 30 550 patients were identified; 26 479 underwent surgery-only, and 4 071 surgery + adjuvant therapy. The surgery-only group (median follow up 8.4 years (IQR 5.9–11.6)) was followed mainly by surgeons, dermatologists, and family physicians. The surgery + adjuvant therapy group (median follow up 8.0 years (IQR 5.5–11.6)) was followed by surgeons, dermatologists, family physicians and medical oncologists. Imaging (CT and lymph node US) was used more frequently in the surgery + adjuvant therapy group. From 2017 onwards, patients had more cross-sectional imaging completed.</div></div><div><h3>Conclusion</h3><div>Variability exists in the surveillance strategies for early stage (I, II) and advanced stage (III) melanoma patients, including clinical visits with various physician groups, and imaging modality and frequency. Such variability may provide a basis for development of future tailored survivorship programmatic development.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"3 2","pages":"Article 100234"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147388324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robotic right hemicolectomy with complete mesocolic excision and D3 lymphadenectomy: Perioperative complications and oncologic outcomes","authors":"Matthew B. Hill ,&nbsp;Thikhamporn Tawantanakorn ,&nbsp;Mithat Gonen ,&nbsp;Julio Garcia-Aguilar ,&nbsp;Martin R. Weiser","doi":"10.1016/j.soi.2025.100213","DOIUrl":"10.1016/j.soi.2025.100213","url":null,"abstract":"<div><h3>Background</h3><div>Hemicolectomy with complete mesocolic excision and D3 lymphadenectomy is associated with high lymph node yield and favorable oncologic outcomes; however, there are concerns over the safety of the procedure given the extent of dissection required.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed the rates of complications and disease-free survival in patients with cancer in the ascending colon, terminal ileum, or appendix who underwent a robotic right hemicolectomy with complete mesocolic excision and D3 lymphadenectomy at our comprehensive cancer center between 2014 and 2024.</div></div><div><h3>Results</h3><div>For the 631 patients included in the analysis, median operative time was 165 (IQR 140–188) min, with median blood loss of 25 (IQR 25–50) ml. Complications of Clavien-Dindo grade ≥III occurred in 15 patients (2.4 %), including 7 patients (1.1 %) with anastomotic leak. Median hospital stay was 4 (IQR 3–5) days, with 38 patients (6.0 %) readmitted and 2 deaths (0.3 %) within 30 days. For 536 patients with colon adenocarcinoma, the median number of lymph nodes harvested was 30.5 (IQR 23–42); with median follow-up of 42.8 months, 2 patients had a local (anastomotic) recurrence and 61 had a distant recurrence. Disease-free survival at 5 years in patients treated for stage I, II, or III colon cancer was 98.5 %, 89.9 %, and 68.6 %, respectively.</div></div><div><h3>Conclusions</h3><div>Robotic right hemicolectomy with complete mesocolic excision and D3 lymphadenectomy can be performed with low morbidity by experienced surgeons. Outcomes compare favorably to the outcomes of standard colectomy and are similar to the outcomes of open and laparoscopic D3 colectomies.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"3 1","pages":"Article 100213"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145938510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selective use of post-lumpectomy mammography after breast-conserving surgery","authors":"Carolyn A. Schnurr ,&nbsp;Danielle J. Hurst ,&nbsp;Kristin E. LeMarbe ,&nbsp;Sevasti A. Vergis ,&nbsp;Thomas J. Quinn ,&nbsp;Joshua T. Dilworth ,&nbsp;Sayee Kiran ,&nbsp;Nayana Dekhne","doi":"10.1016/j.soi.2026.100228","DOIUrl":"10.1016/j.soi.2026.100228","url":null,"abstract":"<div><h3>Objectives</h3><div>Post-lumpectomy mammography (PLM) may detect suspicious residual calcifications after breast-conserving surgery (BCS). However, PLM may lead to patient anxiety, delays in initiating adjuvant treatment, and increased costs. We aimed to identify predictors of suspicious residual calcifications that may be used to select patients for whom PLM may be avoided.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of patients with non-metastatic breast cancer who underwent BCS and PLM between May 2016 to June 2023 at a single institution. We recorded patient characteristics, the presence of suspicious calcifications on pre-operative mammography and PLM, pathology from initial biopsy and lumpectomy specimen, and whether additional biopsy, re-excision, or mastectomy was performed. Wilcoxon Ranked-Sum and Fisher’s Exact tests were used to compare outcomes between cohorts. Univariate (UVA) and multivariable analyses (MVA) identified potential predictors of suspicious residual calcifications on PLM and the need for an additional procedure following PLM.</div></div><div><h3>Results</h3><div>Among 463 patients with pure DCIS (56 %), invasive ductal carcinoma (39.5 %), or invasive lobular carcinoma (4.5 %), 76 (16.4 %) had suspicious residual calcifications on PLM, of whom 70 (41.7 %) underwent an additional procedure, of which 43 (61.4 %) had positive pathology. On MVA, clinical tumor size was a significant predictor of residual calcifications on PLM (odds ratio [OR], 2.38, <em>p</em> = 0.008) and residual calcifications on PLM strongly predicted the likelihood of an additional procedure (odds ratio [OR], 64.9, <em>p</em> &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Our findings suggest that patients with clinically small tumors and clear margins may represent a low-risk group in whom routine PLM could potentially be avoided.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"3 1","pages":"Article 100228"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146077449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy following neoadjuvant systemic therapy for high-volume peritoneal mesothelioma","authors":"Yun Song ,&nbsp;Joelle Allam ,&nbsp;Karen A. Beaty ,&nbsp;Anneleis F. Willett ,&nbsp;Melissa W. Taggart ,&nbsp;Anais Malpica ,&nbsp;Richard E. Royal ,&nbsp;Paul F. Mansfield ,&nbsp;Ryan W. Huey ,&nbsp;Kanwal P.S. Raghav ,&nbsp;Keith F. Fournier ,&nbsp;Beth A. Helmink","doi":"10.1016/j.soi.2025.100209","DOIUrl":"10.1016/j.soi.2025.100209","url":null,"abstract":"<div><h3>Background</h3><div>The role and optimal sequencing of systemic therapy in patients with high-volume peritoneal mesothelioma (PeM) undergoing curative-intent cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) remains unclear. We compared perioperative outcomes in patients undergoing upfront CRS/HIPEC (U-CRS) versus those receiving neoadjuvant therapy (NAT).</div></div><div><h3>Methods</h3><div>This single-institution retrospective study included patients with PeM (2009–2023) who underwent CRS/HIPEC with a peritoneal carcinomatosis index (PCI) &gt; 20. Primary outcomes were prolonged operative time (OT), defined as &gt; 75th percentile for the study cohort, and 90-day postoperative complications. Secondary outcomes included complete cytoreduction with CC-0 score, recurrence-free survival (RFS), and overall survival (OS).</div></div><div><h3>Results</h3><div>Of 45 patients, 14 (31 %) underwent U-CRS and 31 (69 %) received NAT. Most NAT patients (94 %) were treated with a platinum agent and pemetrexed, with or without bevacizumab, for a median of 6 cycles. Median PCI was similar between groups (U-CRS: 28; NAT: 27; <em>p</em> = 0.73). Median OT was 572 min (U-CRS) vs. 645 min (NAT; <em>p</em> = 0.17). Grade III–V complications occurred in 50 % of U-CRS vs. 32 % of NAT patients (<em>p</em> = 0.42). NAT was not independently associated with prolonged OT or severe complications on multivariable analyses. Rates of CC-0 resection, RFS, and OS were similar between groups.</div></div><div><h3>Conclusions</h3><div>NAT is feasible and safe in patients with high-volume PeM undergoing CRS/HIPEC, without negatively affecting perioperative outcomes. The neoadjuvant setting offers a valuable platform for investigating novel therapies aimed at improving long-term outcomes in PeM.</div></div><div><h3>Synopsis</h3><div>Neoadjuvant systemic therapy before CRS/HIPEC for high-volume peritoneal mesothelioma is feasible and safe with similar operative times and complication rates as upfront surgery, supporting its use as a platform to evaluate novel therapies to improve long-term outcomes in peritoneal mesothelioma.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"3 1","pages":"Article 100209"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145840590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal duration of neoadjuvant chemotherapy prior to CRS±HIPEC for colorectal cancer: An assessment of survival and postoperative outcomes","authors":"Frances J. Bennett ,&nbsp;Kailey M. Oppat ,&nbsp;Mohammad Y. Zaidi ,&nbsp;Joshua Winer ,&nbsp;Maria C. Russell ,&nbsp;Charles Staley ,&nbsp;Shishir K. Maithel ,&nbsp;Seth J. Concors","doi":"10.1016/j.soi.2025.100210","DOIUrl":"10.1016/j.soi.2025.100210","url":null,"abstract":"<div><h3>Background</h3><div>Cytoreductive surgery (CRS) with or without heated intraperitoneal chemotherapy (HIPEC) represents a viable therapy for select patients with colorectal cancer (CRC) peritoneal metastases. Given recurrence rates, challenges returning to oncologic treatment postoperatively, and desire to assess tumor biology, neoadjuvant chemotherapy (NAC) is common. Evidence-based guidance regarding NAC duration is limited.</div></div><div><h3>Methods</h3><div>A single institution database (2009–2024) of patients with CRC that underwent CRS±HIPEC was reviewed. Patients undergoing curative intent CRS±HIPEC with known NAC duration were stratified by NAC duration (0–3 vs &gt;3 months). Primary outcomes were recurrence-free survival (RFS) and overall survival (OS). Secondary outcome was clinically significant postoperative complications.</div></div><div><h3>Results</h3><div>From 2009–2024, 87 patients underwent curative intent CRS±HIPEC (&gt;3 months NAC: 58 patients, 0–3 months NAC: 29 patients). Median peritoneal cancer index score was similar between cohorts (&gt;3 months: 11 vs 0–3 months: 12; p = 0.98). RFS and OS were not statistically different based on NAC duration (RFS: &gt;3 months: 8 months vs 0–3 months: 15 months, p = 0.28) (OS: &gt;3 months: 26 months vs 0–3 months: 35 months; p = 0.33). &gt; 3 months of NAC was associated with increased median length of stay (&gt;3 months: 10 days vs 0–3 months: 8 days; p = 0.04). Even when controlling for other perioperative variables on multivariable analysis, &gt; 3 months of NAC was associated with increased risk of clinically significant complications (HR 3.47, 95 % CI 1.11–10.88; p = 0.03).</div></div><div><h3>Conclusion</h3><div>Greater duration of NAC prior to CRS±HIPEC is not associated with improved RFS or OS, and, rather, is associated with higher complication rate and longer hospital stay.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"3 1","pages":"Article 100210"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145840591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of multivisceral resection on outcomes in primary retroperitoneal sarcoma: A systematic review by the Australian and New Zealand Sarcoma Association Clinical Practice Guidelines Working Party","authors":"David J. Coker ,&nbsp;David Gyorki ,&nbsp;Deborah Zhou ,&nbsp;Anna Lawless ,&nbsp;Joanna Connor ,&nbsp;Peter S. Grimison ,&nbsp;Stephen R. Thompson ,&nbsp;Iain Ward ,&nbsp;Elizabeth A. Connolly ,&nbsp;Jasmine Mar ,&nbsp;Smaro Lazarakis ,&nbsp;Scott Venter ,&nbsp;Jean Wong ,&nbsp;Daniel Steffens ,&nbsp;Peter Lee ,&nbsp;Angela M. Hong","doi":"10.1016/j.soi.2025.100208","DOIUrl":"10.1016/j.soi.2025.100208","url":null,"abstract":"<div><h3>Background</h3><div>Retroperitoneal sarcoma (RPS) has high local recurrence rates and poor outcomes, with complete surgical resection being the only curative treatment. Over the past two decades, there has been a trend towards multivisceral resection (MVR). This systematic review sought to evaluate the role of MVR compared with simple resection in patients with primary RPS.</div></div><div><h3>Methods</h3><div>A systematic review was conducted following PICO methodology. Adult patients with primary localized RPS undergoing MVR were compared to those receiving simple resection. Primary outcomes included abdominal recurrence-free survival, overall survival, and perioperative morbidity.</div></div><div><h3>Results</h3><div>Twenty-three retrospective studies were identified, with patient cohorts ranging from 23 to 1007 participants. Results demonstrated conflicting evidence regarding MVR's impact on survival outcomes. The highest quality study showed MVR significantly reduced 3-year abdominal recurrence rates (10 % vs 47 %, HR 1.99, p = 0.04) compared to simple resection. However, MVR did not significantly improve overall survival across most studies. Analysis of perioperative morbidity consistently demonstrated that MVR does not significantly increase complications compared to simple resection.</div></div><div><h3>Conclusions</h3><div>Current evidence suggests MVR may reduce abdominal recurrence in primary RPS without significantly increasing perioperative morbidity, though overall survival benefits remain unproven. MVR could be considered for RPS subtypes at high risk of local recurrence, particularly liposarcoma, to maximize local control without significantly increasing perioperative morbidity. Given that complete surgical resection remains the only curative therapy for RPS, the decision for MVR should be individualized with input from a sarcoma multidisciplinary team.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"3 1","pages":"Article 100208"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145799726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"National trends in emergency and non-emergency colorectal cancer resections across the COVID-19 pandemic","authors":"Trisha Lal ,&nbsp;Christine O. Kang ,&nbsp;Fangzhou Liu ,&nbsp;Alexander Cabulong ,&nbsp;Richard S. Hoehn ,&nbsp;Johnie Rose ,&nbsp;Siran M. Koroukian","doi":"10.1016/j.soi.2025.100197","DOIUrl":"10.1016/j.soi.2025.100197","url":null,"abstract":"<div><div>The enclosed information is STRICTLY CONFIDENTIAL and is intended for the use of the addressee only. University Hospitals and its affiliates disclaim any responsibility for unauthorized disclosure of this information to anyone other than the addressee. Federal and Ohio law protect patient medical information, including psychiatric_disorders, (H.I.V) test results, A.I.Ds-related conditions, alcohol, and/or drug_dependence or abuse disclosed in this email. Federal regulation (42 CFR Part 2) and Ohio Revised Code section 5122.31 and 3701.243 prohibit disclosure of this information without the specific written consent of the person to whom it pertains, or as otherwise permitted by law.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"3 1","pages":"Article 100197"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145646072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association of lymph node ratio to survival in gastric adenocarcinoma patients following radical gastrectomy","authors":"Liliana Cuevas López ,&nbsp;Carlos E. Diaz-Castrillón ,&nbsp;Francisco Javier Henao ,&nbsp;Elio Fabio Sánchez","doi":"10.1016/j.soi.2025.100211","DOIUrl":"10.1016/j.soi.2025.100211","url":null,"abstract":"<div><h3>Objective</h3><div>The TNM staging system offers prognostic insights, but its effectiveness is often limited by inadequate lymph node retrieval. The lymph node ratio (LNR) offers a more comprehensive assessment. This study aimed to evaluate the association between LNR and survival outcomes in Colombia, a country with a high prevalence of gastric cancer.</div></div><div><h3>Methods</h3><div>This retrospective cohort study included patients with gastric adenocarcinoma who underwent oncologic resection at a single center between 2015 and 2018. The LNR was calculated as the ratio of affected lymph nodes to the total number dissected during gastrectomy. Perioperative characteristics were assessed based on LNR quartiles: LNR0 (0), LNR1 (&gt;0–0.16), LNR2 (&gt;0.16–0.4), and LNR3 (&gt;0.4). Kaplan-Meier survival curves and multivariable Cox regression models were used to evaluated the association between LNR and survival outcomes.</div></div><div><h3>Results</h3><div>157 patients were included, with a median age of 64 years; 63.1 % (n = 99) were men, and 74.5 % (n = 117) had an ECOG 1. The median number of lymph nodes collected was 24, with 77 % (n = 122) having more than 15 nodes resected. Significant differences in overall survival (OS) and disease-free survival (DFS) were observed among the LNR groups (p = 0.0010). As LNR increased, both OS and DFS declined. Patients with 40 % LNR involvement had twice the mortality hazard (HR 2.13, 95 % CI 1.02–4.48) and patients with 10 % LNR involvement had three times the recurrence risk (HR 3.12, 95 % CI 1.1–8.82).</div></div><div><h3>Conclusions</h3><div>LNR is an independent prognostic factor for survival following radical gastrectomy. This highlights the need for careful lymph node evaluation and its integration into risk stratification and patient management.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"3 1","pages":"Article 100211"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145884431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights to multidisciplinary care in early onset colorectal cancer","authors":"Casidhe-Nicole Bethancourt ,&nbsp;David Cohen ,&nbsp;Yoanna Pumpalova ,&nbsp;Joel Gabre ,&nbsp;Beatrice Dionigi","doi":"10.1016/j.soi.2025.100214","DOIUrl":"10.1016/j.soi.2025.100214","url":null,"abstract":"<div><div>Early onset colorectal cancer (EO-CRC) is growing steadily, despite increased efforts in screening and early detection. Although genomically similar to average-onset colorectal cancer (AO-CRC), younger patients face distinct clinical, psychosocial and economic challenges. While the general guidelines for detection and treatment are the same across age groups, we aim here to describe some of the unique challenges faced by younger patients. These include diagnostic delays, fertility concerns, and unique emotional and financial burdens. In this review, we explore the multidimensional needs of EO-CRC patients, including barriers to early detection, the impact of treatment on reproductive health and relationships, and the long-term financial and psychological toll. Addressing these challenges requires a tailored, multidisciplinary approach that goes beyond standard oncologic care.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"3 1","pages":"Article 100214"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145977191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Society of surgical oncology medical student & trainee primer for hepatopancreatobiliary surgical oncology","authors":"Lily V. Saadat ,&nbsp;Bridget Kelly ,&nbsp;Micah J. Brainerd ,&nbsp;Marissa K. Boyle ,&nbsp;Brian K. Sparkman ,&nbsp;Kelly L. Koch ,&nbsp;Julia M. Selfridge ,&nbsp;Christopher P. Childers ,&nbsp;Robin Schmitz ,&nbsp;on behalf of the Fellows and Young Attendings Committee of the Society of Surgical Oncology (SSO)","doi":"10.1016/j.soi.2025.100202","DOIUrl":"10.1016/j.soi.2025.100202","url":null,"abstract":"<div><div>The goal of this primer is to educate the future generation of surgeons and prepare trainees for their clinical rotations in the operating room and with patient care. This primer will introduce medical students and trainees to the diagnosis and management of benign and malignant hepatopancreatobiliary (HPB) oncology for their surgical oncology rotations.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"3 1","pages":"Article 100202"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145694612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}